Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Finerenone - Bayer HealthCare Pharmaceuticals

Next Previous
Drug Profile

Finerenone - Bayer HealthCare Pharmaceuticals

Alternative Names: BAY-94-8862; Firialta™; KERENDIA; Kerendia

Latest Information Update: 13 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer HealthCare Pharmaceuticals
  • Class Amides; Antihyperglycaemics; Heart failure therapies; Naphthyridines; Nitriles; Small molecules; Urologics
  • Mechanism of Action Mineralocorticoid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Diabetic nephropathies
  • Preregistration Heart failure
  • Phase III Chronic heart failure; Renal failure; Type 1 diabetes mellitus

Most Recent Events

  • 17 Mar 2025 Finerenone receives priority review status for Heart failure in USA
  • 17 Mar 2025 US FDA accepts sNDA for finerenone for Heart failure for review
  • 14 Mar 2025 Bayer completes a phase II trial in Diabetic nephropathies (Monotherapy, Combination therapy) in Italy, Taiwan, Spain, Netherlands, Netherlands, South Korea, Japan, Israel, Germany, France, France, Canada, Denmark, Belgium, India and USA (PO) (NCT05254002)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top